Deng, H., Huang, Y., Hong, Z., Yuan, X., Cao, Z., Wei, Y., & Zhang, W. (2019). Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: A meta-analysis. BMC Cancer.
シカゴスタイル引用形Deng, Huan, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, , Wenxiong Zhang. "Pazopanib Has Equivalent Anti-tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-analysis." BMC Cancer 2019.
MLA引用形式Deng, Huan, et al. "Pazopanib Has Equivalent Anti-tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-analysis." BMC Cancer 2019.